Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World

U.K.-based short-acting psychedelics developer Small Pharma Inc. DMTTF has been working hard on securing a proprietary IP throughout North America, Australasia and Europe.

CEO George Tziras says the team has made progress in 2023 to further strengthen the company’s IP position in key international markets by building multi-layered IP protection around each pipeline program and thus helping optimize their commercial potential.

“We are pleased that our efforts to invest in developing novel treatment innovations for patients continues to be recognized in multiple jurisdictions,” Tziras added.

The company’s protection strategy includes the discovery of novel drugs and their therapeutic compositions and medical uses, plus the novel synthesis of high-purity drug substances at scale.

Since February, Small Pharma was granted five new patents: two covering the composition of matter for certain deuterated tryptamine homologs (U.S. and N.Z.;) one covering the novel synthesis of high-purity DMT and deuterated DMT analogs at scale (U.S.;) one for a novel injectable formulation of DMT-based compounds (Australia;) and one covering therapeutic solid dosage forms of deuterated DMT analogs (G.B.)

Three additional patents are expected to be granted by May 31, covering the composition of matter of certain deuterated DMT analogs (G.B.) and a group of deuterated DMT homologs (U.S.,) as well as the medical use of certain deuterated DMT analogs (G.B.) 

The company also received five Notices of Allowance on patents covering the composition of matter for a group of deuterated DMT homologs (Europe,) medical use and therapeutic compositions of a group of deuterated DMT homologs (Australia, N.Z. and Japan,) and novel synthesis of high-purity DMT and deuterated DMT analogs at scale (Canada.)

See also: Terran Biosciences' Four Patent Applications Cover Improved Versions Of Classic Empathogens

Small Pharma’s psychedelic IP portfolio consists of 14 granted patents with 87 granted or pending. The drug development pipeline consists of intravenous/intramuscular (IV/IM) DMT compound SPL026, injectable deuterated DMT series SPL028, and oral tryptamine series SPL029.

Photo: Benzinga edit with photo by Photon photo and Jynto on Wikimedia Commons.